Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds-Reference-Cited by-同舟云学术

Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds

Published:2023-03-09 Issue:6 Volume:28 Page:2499
ISSN:1420-3049
Container-title:Molecules
language:en
Short-container-title:Molecules

Author:

Kljun Jakob¹^ORCID,Rebernik Mihaela¹,Balsa Lucía M.²,Kladnik Jerneja¹,Rapuš Uroš¹,Trobec Tomaž³,Sepčić Kristina⁴^ORCID,Frangež Robert³^ORCID,León Ignacio E.²^ORCID,Turel Iztok¹^ORCID

Affiliation:

1. Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia

2. CEQUINOR (UNLP, CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Blvd. 120 N°1465, La Plata 1900, Argentina

3. Institute of Preclinical Sciences, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, SI-1000 Ljubljana, Slovenia

4. Department of Biology, Biotechnical Faculty, University of LjubljanaJamnikarjeva 101, SI-1000 Ljubljana, Slovenia

Abstract

Organoruthenium pyrithione (1-hydroxypyridine-2-thione) complexes have been shown in our recent studies to be a promising family of compounds for development of new anticancer drugs. The complex [(η6-p-cymene)Ru(pyrithionato)(pta)]PF6 contains phosphine ligand pta (1,3,5-triaza-7-phosphaadamantane) as a functionality that improves the stability of the complex and its aqueous solubility. Here, we report our efforts to find pta alternatives and discover new structural elements to improve the biological properties of ruthenium anticancer drugs. The pta ligand was replaced by a selection of phosphine, phosphite, and arsine ligands to identify new functionalities, leading to improvement in inhibitory potency towards enzyme glutathione S-transferase. In addition, cytotoxicity in breast, bone, and colon cancers was investigated.

Funder

Slovenian Research Agency

Universidad Nacional de La Plata

Consejo Nacional de Investigaciones Científicas y Técnicas

Agencia Nacional de Promoción Científica y Tecnológica

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Link

https://www.mdpi.com/1420-3049/28/6/2499/pdf

Reference44 articles.

1. Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation;Sadler;Inorg. Chem.,2013

2. Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective;Alessio;Eur. J. Inorg. Chem.,2017

3. Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy;Leijen;Investig. New Drugs,2015

4. Preclinical activity of trans-indazolium [tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR.; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells;Depenbrock;Eur. J. Cancer,1997

5. The development of RAPTA compounds for the treatment of tumors;Murray;Coord. Chem. Rev.,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metallocompounds as anticancer agents against osteosarcoma;Drug Discovery Today;2024-09